Chlamydia Infections Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com

Chlamydia Infections Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com




Chlamydia Infections Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chlamydia Infections (Infectious Disease) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

Chlamydia Infections – Drugs In Development, 2021, provides an overview of the pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

Report Highlights

Chlamydia Infections – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

Introduction

Chlamydia Infections – Overview

  • Chlamydia Infections – Therapeutics Development

Pipeline Overview

  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Chlamydia Infections – Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Chlamydia Infections – Companies Involved in Therapeutics Development

  • Abera Bioscience AB
  • Abivax SA
  • BlueWillow Biologics Inc
  • Erganeo
  • Eurocine Vaccines AB
  • Evofem Biosciences Inc
  • Genetic Immunity Inc
  • Lead Discovery Center GmbH
  • Merck & Co Inc
  • Microbiotix Inc
  • QureTech Bio AB
  • Traccine Pharmaceuticals
  • Vault Pharma Inc
  • Vaxine Pty Ltd
  • Yaso Therapeutics Inc

Chlamydia Infections – Drug Profiles

  • Ab-03 – Drug Profile
  • ABX-196 – Drug Profile
  • ChlamyDerm – Drug Profile
  • Chlamydia vaccine – Drug Profile
  • PEG-2S – Drug Profile
  • Peptide to Inhibit CPAF for Chlamydia Infections – Drug Profile
  • PPCM – Drug Profile
  • Small Molecule for Chlamydia Infections – Drug Profile
  • Small Molecules to Block Virulence for Chlamydia Infections – Drug Profile
  • Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections – Drug Profile
  • solithromycin – Drug Profile
  • VPI-201 – Drug Profile

Chlamydia Infections – Dormant Projects

Chlamydia Infections – Product Development Milestones

Featured News & Press Releases

  • May 17, 2021: New data on EVO100 for the prevention of chlamydia and gonorrhea in women to be presented at ISPOR 2021
  • Mar 31, 2021: Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia
  • Mar 16, 2021: Evofem Biosciences announces publication in American Journal of Obstetrics and Gynecology of AMPREVENCE study of EVO100 for chlamydia and gonorrhea prevention
  • Feb 25, 2021: Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate
  • Dec 30, 2020: Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan
  • Dec 30, 2020: Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
  • Dec 22, 2020: Evofem Biosciences to participate in Medicaid National Drug Rebate Program for Phexxi effective January 1, 2021
  • Dec 21, 2020: Evofem Biosciences to present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
  • Dec 17, 2020: Evofem Biosciences provides update on pivotal phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea
  • Dec 11, 2020: Evofem Biosciences announces orange book listing of two U.S. patents for Phexxi
  • Dec 03, 2020: The U.S. Department of Veterans Affairs awards contract to Evofem Biosciences for Phexxi
  • Oct 20, 2020: Evofem Biosciences announces first patient enrolled in pivotal phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea
  • Sep 14, 2020: Evofem Biosciences to present data at the 2020 STD prevention virtual conference from phase 2b trial of EVO100 for prevention of chlamydia and gonorrhea in women
  • May 12, 2020: Eurocine Vaccines receives notification of grant to prepare for the manufacture of the chlamydia vaccine candidate
  • May 07, 2020: Eurocine Vaccines presents end results from preclinical study with chlamydia vaccine

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/re1m1a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900